Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

LCH Risk Organ Classification

Langerhans Cell Histiocytosis (LCH) is stratified based on the extent of disease (Single System vs.

Evidence-based context for fast calculator use

Purpose:
LCH Risk Organ Classification stratifies Langerhans cell histiocytosis by system involvement to guide treatment intensity decisions.
Population:
patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria
Factors:
Number of Organ Systems Involved, Liver Involvement?, Spleen Involvement?, Hematopoietic Involvement?
Reference:
Allen CE, et al. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379(9):856-868.
HomeLCH Risk Organ Classification
Pin your most used calculators here by clicking the star in the dropdown.

LCH Risk Organ Classification

Clinical Context & Background

Langerhans Cell Histiocytosis (LCH) is stratified based on the extent of disease (Single System vs. Multisystem) and the involvement of "Risk Organs" (Liver, Spleen, Hematopoietic System). Risk Organ involvement is the most significant prognostic factor for mortality.
Primary Source EvidenceAllen CE, et al. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379(9):856-868.
Formula Logic
Classification based on organ involvement.

Reference Data

GroupDefinitionPrognosis
Single System (SS-LCH)One organ/system involved (e.g. Bone, Skin)Excellent survival
Multisystem (MS-LCH) RO-Multiple systems, No Risk OrgansVery good survival, reactivation common
Multisystem (MS-LCH) RO+Involvement of Liver, Spleen, or MarrowHigher mortality risk

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use LCH Risk Organ Classification when lCH Risk Organ Classification stratifies Langerhans cell histiocytosis by system involvement to guide treatment intensity decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Single System (SS-LCH) through Multisystem (MS-LCH) RO+.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm pathology, organ involvement, infectious and malignant mimics, laboratory trends, and urgent specialist input.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Classification and hyperinflammation scores do not replace diagnostic criteria or emergency treatment assessment.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria

How to apply this result

For a representative case, verify Number of Organ Systems Involved, Liver Involvement?, Spleen Involvement?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

HLH-2004 Diagnostic Criteria Calculator — Hemophagocytic LymphohistiocytosisHScore for HLHAnn Arbor Staging (Histiocytic Sarcoma)

Frequently Asked Questions

When should LCH Risk Organ Classification be used?

Use it for patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria when all required inputs and the intended clinical setting are confirmed.

Can LCH Risk Organ Classification determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.